CIRM: The Good, the Bad, and the Ugly

See allHide authors and affiliations

Science  24 Dec 2010:
Vol. 330, Issue 6012, pp. 1742-1743
DOI: 10.1126/science.330.6012.1742

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


December has been an eventful month for the California Institute for Regenerative Medicine (CIRM), the agency created by California voters to disburse $3 billion for stem cell research. Robert Klein had promised to step down as chair when his term expired on 17 December. On 15 December, CIRM's governing board was scheduled to elect Klein's successor. But the candidacy of Klein's chosen successor, Alan Bernstein, a Canadian scientist and executive director of the Global HIV Vaccine Enterprise, ran aground because of concerns that state law precludes non-U.S. citizens from holding the job, and then another candidate accepted the nomination only to withdraw 8 days later. Despite all this, many scientists insist that the institute has been a tremendous success.